Lantheus (NASDAQ:LNTH) Shares Sold Off by Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Lantheus Holdings, Inc. (NASDAQ:LNTH). In a filing disclosed on November 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Lantheus stock on October 15th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 11/2/2026.
• Purchased $1,001 – $15,000 in shares of argenex (NASDAQ:ARGX) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Illumina (NASDAQ:ILMN) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Revvity (NYSE:RVTY) on 10/27/2026.
• Sold $15,001 – $50,000 in shares of PTC (NASDAQ:PTC) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Micron Solutions (OTCMKTS:MICR) on 10/21/2026.
• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/21/2026.
• Purchased $1,001 – $15,000 in shares of ServiceNow (NYSE:NOW) on 10/21/2026.

Lantheus Price Performance

Shares of LNTH stock traded down $0.35 during trading on Thursday, hitting $101.25. The company had a trading volume of 1,193,845 shares, compared to its average volume of 1,099,041. The stock’s 50-day moving average is $100.31 and its two-hundred day moving average is $92.74. The stock has a market capitalization of $6.62 billion, a price-to-earnings ratio of 18.75 and a beta of 0.01. The company has a quick ratio of 3.06, a current ratio of 3.25 and a debt-to-equity ratio of 0.42. Lantheus Holdings, Inc. has a 52 week low of $51.47 and a 52 week high of $111.86.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, November 5th. The medical equipment provider reported $1.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.45. Lantheus had a return on equity of 29.26% and a net margin of 17.28%. The firm had revenue of $389.91 million during the quarter, compared to analyst estimates of $355.74 million. During the same quarter in the previous year, the company posted $1.27 earnings per share. The company’s revenue was up 1.5% compared to the same quarter last year. As a group, analysts predict that Lantheus Holdings, Inc. will post 4.54 EPS for the current fiscal year.

Institutional Trading of Lantheus

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LNTH. First Trust Advisors LP lifted its position in shares of Lantheus by 24.4% in the 3rd quarter. First Trust Advisors LP now owns 96,348 shares of the medical equipment provider’s stock worth $9,590,000 after purchasing an additional 18,891 shares during the period. Global Retirement Partners LLC increased its position in shares of Lantheus by 934.5% during the third quarter. Global Retirement Partners LLC now owns 6,652 shares of the medical equipment provider’s stock valued at $662,000 after buying an additional 6,009 shares during the period. Teachers Retirement System of The State of Kentucky increased its position in shares of Lantheus by 4.5% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 38,327 shares of the medical equipment provider’s stock valued at $3,815,000 after buying an additional 1,656 shares during the period. New York Life Investment Management LLC purchased a new position in shares of Lantheus during the third quarter valued at about $5,965,000. Finally, Retirement Systems of Alabama raised its stake in Lantheus by 16.2% in the third quarter. Retirement Systems of Alabama now owns 186,010 shares of the medical equipment provider’s stock worth $18,514,000 after buying an additional 25,967 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on LNTH. TD Cowen cut shares of Lantheus from a “buy” rating to a “hold” rating and cut their price objective for the company from $110.00 to $102.50 in a research note on Monday, August 3rd. B. Riley Financial cut shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Monday, August 17th. Leerink Partners set a $102.50 price target on shares of Lantheus in a research note on Monday, August 3rd. William Blair set a $102.50 price target on shares of Lantheus in a research note on Monday, August 3rd. Finally, Weiss Ratings lowered shares of Lantheus from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, October 15th. Three research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company’s stock. Based on data from MarketBeat, Lantheus currently has a consensus rating of “Hold” and an average target price of $107.44.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Lantheus

Lantheus Holdings is a radiopharmaceutical and medical imaging company that develops, manufactures, and commercializes products used to diagnose and manage disease. Its offerings support imaging across several areas of medicine, including oncology and cardiology. The company’s products include Pylarify, a positron emission tomography (PET) imaging agent used to detect prostate cancer; Definity, an ultrasound contrast agent used in cardiac imaging; and TechneLite, a generator that supplies technetium-99m for diagnostic imaging procedures.